Skip to content

uniQure QURE Proceeds From Royalty Financing Agreement Net Of Issuance Costs

Proceeds From Royalty Financing Agreement Net Of Issuance Costs at other companies

Jaguar Uranium
 logo
Jaguar Uranium JAGU
$315K
Nuvation Bio logo
Nuvation BioNUVB
$864K
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$343.91M+3.7%
Aaon logo
AaonAAON
$0-100%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$8.47M-41.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.25M

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept qure:ProceedsFromRoyaltyFinancingAgreementNetOfIssuanceCosts.

The official record: uniQure’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's proceeds from royalty financing agreement net of issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's proceeds from royalty financing agreement net of issuance costs?
uniQure (QURE) reported proceeds from royalty financing agreement net of issuance costs of $92.52M in Q4 2023.
What does proceeds from royalty financing agreement net of issuance costs mean?
This represents the net cash proceeds received from entering into agreements that monetize future royalty streams from products or intellectual property. It is a strategic financing tool used to generate upfront capital without immediate equity dilution. It is vital for evaluating how the company funds R&D by leveraging future revenue potential.